CD19 and neoplasm: The intrinsic sensitivity of the TCAR could be used for the treatment of antigen-low solid tumor entities or hematologic malignancies such as CD19 leukemia or lymphomas to prevent relapse of B cell–derived tumor cells (54), the latter even providing costimulation in trans.